Proteome Sciences

Proteome Sciences is a London (UK) and Frankfurt (Germany) based SME with expertise in proteomics and biomarker research. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies. Our PS Biomarker Services for discovery and validation of biomarkers includes gel-based and gel-free separations linked to tandem mass spectrometry. We use proprietary isobaric tagging for higher throughput and better precision in biomarker discovery. We have also developed identical isotopic tags for rapid development of biomarker validation assays using isotope dilution mass spectrometry and Selected Reaction Monitoring (SRM). Such MS-based assays are rapid to develop compared to immunoassay and have potential for high rates of multiplexing. Proteome Sciences also provides analysis of post-translational modifications (PTM) and assays for such PTMs. We have wide experience across the life sciences sector working with many different human and animal sample types including blood plasma, CSF, solid tissues, cell culture material etc. As a reflection of the quality of our approach, the purpose built, state-of-the-art research facility in Frankfurt is certified to ISO 9001:2008.
Type
Public
HQ
Cobham, GB
Employees
36 (est)
Proteome Sciences is headquartered in Cobham, GB

Proteome Sciences Locations

Cobham, GB

Proteome Sciences Metrics

Proteome Sciences Summary

Market capitalization

£12.9 M

Closing share price

£0.0564
Proteome Sciences's latest market capitalization is £12.9 M.

Proteome Sciences Market Value History

14% of current employees of Proteome Sciences are female and 86% are male.

Proteome Sciences News

Proteome Sciences Company Life

You may also be interested in